Table 2 Clinical characteristics of nine typical participants
Group | Age | Sex | ADAS-Cog | MMSE | Amyloid PET |
|---|---|---|---|---|---|
GR1 | 60 | F | 18 | 25 | Positive |
GR2 | 61 | F | 13 | 29 | Positive |
GR3 | 67 | F | 22 | 22 | Positive |
PR1 | 60 | F | 24 | 25 | Positive |
PR2 | 65 | F | 19 | 24 | Positive |
PR3 | 58 | F | 20 | 25 | Positive |
Placebo1 | 71 | M | 21 | 26 | Positive |
Placebo2 | 64 | F | 24 | 19 | Positive |
Placebo3 | 56 | F | 26 | 18 | Positive |